Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement

Alan, 2020, How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature, J Oncol. Pharm. Pract. [Internet], 26, 1011, 10.1177/1078155219879757 Antonescu, 2015, Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement, Am. J. Surg. Pathol., 39, 957, 10.1097/PAS.0000000000000404 Co, 2007, Inflammatory myofibroblastic tumor, Am. J. Surg. Pathol., 31, 12 Gambacorti-Passerini, 2018, Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study, Am. J. Hematol. [Internet], 93, 607, 10.1002/ajh.25043 Gaudichon, 2016, Complete and repeated response of a metastatic ALK-rearranged Inflammatory myofibroblastic tumor to crizotinib in a teenage girl, J. Pediatric Hematol./Oncol. [Internet], 38, 308, 10.1097/MPH.0000000000000498 Gleason, 2008, Inflammatory myofibroblastic tumours: where are we now?, J. Clin. Pathol. [Internet], 61, 428, 10.1136/jcp.2007.049387 Jacob, 2014, An unusual case of systemic inflammatory myofibroblastic tumor with successful treatment with ALK-inhibitor, Case Reports Pathol. [Internet], 1 Panagiotopoulos, 2015, Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm?, J. Thoracic Dis., 7, 4 Russo, 2016, Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance, Expert Rev. Anticancer Therapy [Internet], 16, 615, 10.1080/14737140.2016.1182427 Surabhi, 2016, Inflammatory Myofibroblastic Tumors, Radiol. Clin. North Am. [Internet], 54, 553, 10.1016/j.rcl.2015.12.005 Tamura, 2017, Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK -Positive Non–Small-Cell Lung Cancer: AF-001JP, JCO [Internet], 35, 1515, 10.1200/JCO.2016.70.5749 Telugu, 2017, Clinicopathological study of 18 cases of inflammatory myofibroblastic tumors with reference to ALK-1 expression: 5-year experience in a tertiary care center, J. Pathol. Transl. Med. [Internet], 51, 255, 10.4132/jptm.2017.01.12 Tsakiri, 2017, Crizotinib failure in a TPM4-ALK –rearranged inflammatory myofibroblastic tumor with an emerging ALK kinase domain mutation, JCO Precision Oncol. [Internet], 1